Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07229157 · ClinicalTrials.gov registry record · Phase 1
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
A Phase 1 study of Obesity and Overweight, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 2
- Study locations
NCT07229157: Active Phase 1 study of Obesity and Overweight, sponsored by Amgen.
NCT07229157 is a Phase 1 study of Obesity and Overweight that is active but no longer recruiting, run by Amgen. The registered enrollment target is 81 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07229157, a Phase 1 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.
Primary Outcome
Change from baseline in QTcF for maridebart cafraglutide will be the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QTcF after maridebart cafraglutide dosing.
Conditions Studied
Interventions
- DRUG Moxifloxacin
- DRUG Maridebart Cafraglutide
- DRUG Placebo for Maridebart Cafraglutide
- DRUG Placebo for Moxifloxacin
Study Locations (2)
Florida
- Fortrea Clinical Research Unit - Daytona Beach - Daytona Beach
Texas
- Fortrea Clinical Research Unit - Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2026-08-26 |
| Phase | Phase 1 |
What the registry record for NCT07229157 still lists
NCT07229157 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT07229157 reports a single indexed study location in Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07229157 about?
NCT07229157 is a clinical study titled "Effect of Maridebart Cafraglutide on the Heart's Electrical Activity". The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.
What is the current status of trial NCT07229157?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2025-10-22. Estimated completion is 2026-08-26.
What conditions does trial NCT07229157 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07229157?
The interventions under investigation include: Moxifloxacin (DRUG), Maridebart Cafraglutide (DRUG), Placebo for Maridebart Cafraglutide (DRUG), Placebo for Moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT07229157?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07229157 being conducted?
This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07229157's enrollment target sits among peer trials
81 543rd of 1053 higher than 509 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI